High Insider Ownership Growth Stocks To Watch In August 2026
Over the last 7 days, the United States market has experienced a 2.1% drop, yet it remains up by 19% over the past year with earnings projected to grow by 17% annually in the coming years. In such an environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business and potential for sustained performance amidst fluctuating market conditions.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Uxin (UXIN) | 34.3% | 69.4% |
| Upstart Holdings (UPST) | 13.9% | 66.5% |
| Precigen (PGEN) | 11.7% | 55.4% |
| Karman Holdings (KRMN) | 14.9% | 54% |
| Hinge Health (HNGE) | 16.3% | 27.1% |
| Himax Technologies (HIMX) | 29.2% | 70.2% |
| Dave (DAVE) | 17.2% | 23% |
| Carlyle Group (CG) | 27.5% | 20.5% |
| Astera Labs (ALAB) | 10% | 33.2% |
| Almonty Industries (ALM) | 10.8% | 37.1% |
Here's a peek at a few of the choices from the screener.
Abeona Therapeutics (ABEO)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening diseases in the United States, with a market cap of $340.82 million.
Operations: The company's revenue is primarily generated from its biotechnology startups segment, which amounts to $25.52 million.
Insider Ownership: 16.2%
Return On Equity Forecast: N/A (2029 estimate)
Abeona Therapeutics is experiencing substantial revenue growth, with forecasts suggesting a 42.2% annual increase, outpacing the broader US market. Despite recent insider selling, the company remains undervalued by trading significantly below its estimated fair value. Abeona's innovative gene therapy product ZEVASKYN has received NTAP status from CMS, enhancing reimbursement prospects. However, recent earnings showed a net loss of US$20.19 million for Q2 2026 despite increased revenues to US$11.38 million from the previous year.
- Get an in-depth perspective on Abeona Therapeutics' performance by reading our analyst estimates report here.
- Insights from our recent valuation report point to the potential undervaluation of Abeona Therapeutics shares in the market.
Clearfield (CLFD)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Clearfield, Inc. designs, manufactures, and distributes fiber management, protection, and delivery products both in the United States and internationally with a market cap of $374.10 million.
Operations: The company's revenue segment, amounting to $153.66 million, is derived from its operations in fiber management, protection, and delivery products both domestically and internationally.
Insider Ownership: 18.5%
Return On Equity Forecast: N/A (2029 estimate)
Clearfield is poised for growth with a forecasted revenue increase of 17.5% annually, surpassing the US market's average. Despite recent index reclassifications, insider activity shows more buying than selling over the past three months, indicating confidence in its future prospects. Recent earnings revealed improved net income of US$3 million for Q3 2026 compared to last year. Clearfield's expanded fiber portfolio offers advanced monitoring solutions, potentially enhancing infrastructure management and reducing operational disruptions.
- Click to explore a detailed breakdown of our findings in Clearfield's earnings growth report.
- Insights from our recent valuation report point to the potential overvaluation of Clearfield shares in the market.
Lifeway Foods (LWAY)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Lifeway Foods, Inc. produces and markets probiotic-based products in North America, with a market cap of $392.17 million.
Operations: The company's revenue is primarily derived from its cultured dairy products segment, which generated $242.41 million.
Insider Ownership: 32.7%
Return On Equity Forecast: 20% (2029 estimate)
Lifeway Foods is positioned for growth with forecasted earnings to rise significantly at 34.5% annually, outpacing the US market. Despite trading well below estimated fair value, recent insider activity shows more selling than buying in the past three months. Recent Q2 results revealed increased sales to US$66.89 million, but net income dropped sharply from last year. Governance concerns persist following the termination of a poison pill under shareholder pressure.
- Dive into the specifics of Lifeway Foods here with our thorough growth forecast report.
- Our expertly prepared valuation report Lifeway Foods implies its share price may be lower than expected.
Seize The Opportunity
- Click here to access our complete index of 185 Fast Growing US Companies With High Insider Ownership.
- Seeking Other Investments? Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com